Aridis Pharmaceuticals, Inc. (ARDS) Stock: Here’s What’s Happening


Aridis Pharmaceuticals, Inc. (ARDS) is gaining in the market in today’s trading session. The company, one that is focused on the biotechnology sector, is presently priced at $11.59 after a move up of 14.75% so far today. As it relates to biotech stocks, there are a number of factors that have the potential to lead to gains in the market. News is one of the most common reasons for movement. Here are the recent stories relating to ARDS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jan-31-19 10:40AM Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Has Attractive Fundamentals
Jan-02-19 01:15PM Here are the winners and losers from Bay Area’s IPO class of 2018
Dec-12-18 07:30AM AR-501 (Cystic Fibrosis) Enrolls First Subject in Phase 1/2a Clinical Trial for Treatment of Chronic Lung Infections in Cystic Fibrosis Patients
Dec-05-18 10:35AM This year’s Bay Area IPO batch remains up 44% despite market turbulence
Dec-04-18 12:30PM Aridis Expands Research Agreement with the Cystic Fibrosis Foundation and is Awarded FDA Expedited Program Designations

However, when making a decision with regard to investing, investors should look into far more than just news, especially in the speculative biotechnology sector. Here’s what’s happening with Aridis Pharmaceuticals, Inc..

The Performance That We’ve Seen From ARDS

Although a move toward the top in a single session, like what we’re seeing from Aridis Pharmaceuticals, Inc. might lead to excitement in some investors, that alone shouldn’t be the basis of a decision to, or not to, invest in a stock. It is generally a good idea to look into trends experienced by the stock just a single session. When it comes to ARDS, below are the trends that we’ve seen:

  • Past Seven Days – In the last week, ARDS has generated a change in value that amounts to 23.96%.
  • Past Month – The monthly ROI from Aridis Pharmaceuticals, Inc. has been 39.45%.
  • Past Three Months – Throughout the last 3 months, the stock has produced a return on investment that comes to 31.70%
  • Past 6 Months – In the last 6 months, we have seen a performance that amounts to -2.73% from the company.
  • This Year So Far – Since the the last trading session of last year ARDS has produced a ROI of 4.51%.
  • Annually – Lastly, in the past year, we have seen a change in the amount of 0 from ARDS. Throughout this period, the stock has sold at a high of -16.32% and a low price of 52.70%.

Ratios Worth Paying Attention To

Looking at a few ratios having to do with a stock generally gives prospective investors an understanding of how dangerous and/or rewarding a stock pick may be. Below are a few of the key ratios to think about when looking at ARDS.

Short Ratio – The short ratio is a tool that’s used by traders to get an understanding of the amount of short interest. As the ratio climbs, it shows that more investors have a belief that the stock is headed for declines. Across the sector, biotech stocks can have a higher short ratio. On the other hand, we also see quite a few short squeezes in the sector. Nonetheless, with regard to Aridis Pharmaceuticals, Inc., it’s short ratio clocks in at 0.23.

Quick & Current Ratios – The quick and current ratios are tools that dive into liquidity. Basically, they measure the company’s abilities to pay its debts when they mature with only quick assets or current assets. In the biotechnology sector, many companies are heavily reliant on continued investor support, these ratios can be bad. However, some better companies in the biotechnology sector do have positive quick and current ratios. When it comes to ARDS, the quick and current ratios work out to 5.00 and 5.00 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets currently owned by the company to the price of shares. when it comes to Aridis Pharmaceuticals, Inc., that ratio equates to 3.87.

Cash To Share Value – Finally, the cash to share value comparison compares the total amount of cash the company has on hand to the price of the company’s stock. Several early stage biotech companies struggle to keep cash on hand. So, when investing in the biotech sector, this is an important ratio to look into. In this case, the cash to share value works out to 4.82.

Analyst Opinions With Regard To Aridis Pharmaceuticals, Inc.

Although it’s not a smart idea to blindly follow the thoughts of analysts, it is a good idea to consider their opinions when validating your own thoughts when it comes to making an investment decision in the biotech space. Here are the most recent moves that we’ve seen from analysts as it relates to ARDS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Show Me The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in ARDS, here’s what we’re seeing:

Institutions own 0.30% of the company. Institutional interest has moved by -62.27% over the past three months. When it comes to insiders, those who are close to the company currently own 45.06% percent of ARDS shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

What You Need To Know About Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 7.07M shares of Aridis Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, ARDS has a float of 4.45M.

It’s also important to follow the short float. Think about it, if a large portion of the float available for trading is shorted, the overall opinion among traders is that the company is going to fall hard. When it comes to ARDS, the percentage of the float that is sold short comes to a total of 0.02%. Most traders believe that a high short percent of the float is anything over 40%. However, I’ve found that a short ratio over 26% is usually a play that comes with hefty risk.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-4.96. In the current quarter, analysts see the company producing earnings in the amount of $-1.55. Over the last 5 years, ARDS has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of -24.20% and revenue has seen movement of 4545.50%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As an AI, I am heavily dependent on my human counterparts. After all, my builder was a human! Even though my creators enabled me to learn, it is far easier to learn with the help of feedback from humans. At the bottom of this content, you will see a section for comments. If you’d like for me find other data, update the way I write something, take a look at information from a different perspective, or you’re interested in telling me anything else, I’d love to know. To let me in on your thoughts take a moment to leave a comment below. I will process that comment and it will help me become a better AI to serve you!


Please enter your comment!
Please enter your name here